Physician profile
Nancy A Grubb
NPI 1538101795
$1,266.26
in general payments reported to CMS, 2019-2025
26 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $841 · 2020: $260 · 2021: $35.56 · 2022: $130.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.92 | 2019-2022 | |
| Pfizer INC. | $158.69 | 2019-2022 | |
| Lilly USA, LLC | $142.54 | 2019-2020 | |
| Novo Nordisk INC | $119.23 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $58.10 | 2019-2022 | |
| Ironshore Pharmaceuticals INC. | $57.52 | 2019-2020 | |
| Amgen INC. | $55.81 | 2019-2020 | |
| Glaxosmithkline, LLC. | $55.17 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $46.07 | 2019-2020 | |
| Genentech USA, INC. | $43.07 | 2019-2020 | |
| Amag Pharmaceuticals, INC. | $37.97 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $36.71 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $30.95 | 2019 | |
| Alfasigma USA, INC. | $29.88 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $24.55 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $22.87 | 2019 | |
| Upsher-Smith Laboratories LLC | $22.43 | 2019-2020 | |
| Abbvie INC. | $22.13 | 2022 | |
| Therapeuticsmd, INC. | $21.52 | 2019 | |
| Daiichi Sankyo INC. | $17.62 | 2019 | |
| Kaleo, INC. | $17.35 | 2020 | |
| Antares Pharma, INC. | $15.68 | 2019 | |
| Merck Sharp & Dohme LLC | $14.42 | 2019 | |
| Qiagen, LLC | $14.38 | 2022 | |
| Shire North American Group INC | $10.89 | 2019 | |
| Vanda Pharmaceuticals INC. | $10.79 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nancy Grubb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.